Know Cancer

or
forgot password

Phase II Randomized Trial With A Modified Dose & Schedule of Subcutaneously Administered Azacitidine & Erythropoietin v Azacitidine Alone in Patients With Low-Risk Myelodysplastic Syndromes (Less Than 11% Marrow & Peripheral Blood Blasts)


Phase 2
18 Years
N/A
Not Enrolling
Both
Myelodysplastic Syndromes

Thank you

Trial Information

Phase II Randomized Trial With A Modified Dose & Schedule of Subcutaneously Administered Azacitidine & Erythropoietin v Azacitidine Alone in Patients With Low-Risk Myelodysplastic Syndromes (Less Than 11% Marrow & Peripheral Blood Blasts)


OUTLINE: This is an open label, multi-center, randomized study.

Eligible patients will be randomized to one of two treatment arms:

Arm A (Azacitidine + Erythropoietin)

- Azacitidine Treatment 50 mg/m2 subcutaneously every other day (three times a week) for
two consecutive weeks every four weeks. A cycle of therapy is defined as two
consecutive weeks of subcutaneous azacitidine administered every other day three times
a week (e.g. Monday - Wednesday - Friday) and the time to resolution of any treatment
associated toxicity.

- Erythropoietin Treatment Patients who are randomized to Arm A will receive a dose of
60,000IU as a single subcutaneous injection weekly without interruption while enrolled
on protocol therapy. The dose should be administered to coincide with the first day of
each cycle.

- Protocol therapy may be administered for up to six cycles of therapy.

Arm B (Azacitidine Alone)

- Azacitidine Treatment 50 mg/m2 subcutaneously every other day (three times a week) for
two consecutive weeks every four weeks. A cycle of therapy is defined as two
consecutive weeks of subcutaneous azacitidine administered every other day three times
a week (e.g. Monday - Wednesday - Friday) and the time to resolution of any treatment
associated toxicity.

- Protocol therapy may be administered for up to six cycles of therapy.

ECOG performance status 0 to 2

Hematopoietic:

To be eligible for randomization, subjects must have documentation of at least 1 of the
following:

- A transfusion dependent anemia (defined by a history of two or more episodes of
transfusion within a period of 8 weeks).

- An untransfused hemoglobin < 10 gm/dl measured on at least two occasions more than 7
days apart in the month prior to randomization.

Patients must also meet 1 of the following criteria:

- Has not received prior erythropoietin and has a serum erythropoietin level > 200 IU/L
within 14 days of randomization.

- Has received prior erythropoietin without clinical benefit in the judgment of the
treating physician.

- Adequate iron status defined as serum ferritin > 20 ng/ml and transferrin saturation of
> 30% within 90 days prior to randomization.

- Symptoms attributed to the anemia with hemoglobin < 11 g/dL.

- Folate and Vitamin B12 levels within normal limits within 90 days prior to
randomization.

Hepatic:

- SGOT (ALT) level < 2 x ULN within 14 days prior to randomization.

- SGPT (AST) level < 2 x ULN within 14 days prior to randomization.

- Serum total bilirubin level < 2 x ULN within 14 days prior to randomization.

Renal:

- Serum creatine < 1.5 x the upper limit of normal (ULN) within 14 days prior to
randomization.

Cardiovascular:

- No uncontrolled hypertension (defined as a systolic pressure > 160 mmHg and/or a
diastolic pressure > 110 mmHg).

- No history of (within 12 months) deep venous thrombosis (DVT), pulmonary embolism
(PE), or other venous thrombosis. Prior superficial thrombophlebitis is not an
exclusion criterion.

- No history of (within 6 months) cerebrovascular accident ([CVA] includes ischemic,
embolic, and hemorrhagic), transient ischemic attack (TIA), myocardial ischemia
(includes Unstable Angina, Q wave Myocardial Infarction [QwMI], and non-Q wave
Myocardial Infarction [NQMI]), or other arterial thrombosis.


Inclusion Criteria:



- A bone marrow (BM) aspirate and biopsy that demonstrates MDS with less than 11%
blasts.

- Conventional metaphase cytogenetics done within 90 days prior to registration for
screening.

- Central pathology review, correlative submission and confirmation of diagnosis is
required prior to initiation of therapy (see Study Procedure Manual for details of
submission). The FAB and WHO classification of MDS and the IPSS score will be
determined at time of central pathology review.

- Correlative marrow aspirate obtained.

To be eligible for randomization, subjects must have documentation of at least 1 of the
following:

- A transfusion dependent anemia (defined by a history of two or more episodes of
transfusion within a period of 8 weeks).

- An untransfused hemoglobin < 10 gm/dl measured on at least two occasions more than 7
days apart in the month prior to randomization.

Patients must also meet 1 of the following criteria:

- Has not received prior erythropoietin and has a serum erythropoietin level > 200 IU/L
within 14 days of randomization.

- Has received prior erythropoietin without clinical benefit in the judgment of the
treating physician.

- Adequate iron status defined as serum ferritin > 20 ng/ml and transferrin saturation
of > 30% within 90 days prior to randomization.

- Symptoms attributed to the anemia with hemoglobin < 11 g/dL.

- Folate and Vitamin B12 levels within normal limits within 90 days prior to
randomization.

- Life expectancy > 6 months as judged by the treating investigator.

Exclusion Criteria:

- No known history of intolerance to erythropoietic agents.

- No prior intensive cytotoxic chemotherapy for a myeloid malignancy including MDS.

- Patients with a history of a non-myeloid malignancy with secondary MDS are eligible
for study enrollment provided, in the opinion of the treating investigator and the
study chair, the anticipated behavior of the non-myeloid malignancy will not
interfere with study participation and evaluation of outcome.

- No known or suspected hypersensitivity to azacitidine or mannitol.

- No hepatic tumors.

- No uncontrolled hypertension (defined as a systolic pressure > 160 mmHg and/or a
diastolic pressure > 110 mmHg).

- No known hypersensitivity to mammalian cell-derived products or human albumin.

- No history of (within 12 months) deep venous thrombosis (DVT), pulmonary embolism
(PE), or other venous thrombosis. Prior superficial thrombophlebitis is not an
exclusion criterion.

- No history of (within 6 months) cerebrovascular accident ([CVA] includes ischemic,
embolic and hemorrhagic), transient ischemic attack (TIA), myocardial ischemia
(includes Unstable Angina, Q wave Myocardial Infarction [QwMI] and non-Q wave
Myocardial Infarction [NQMI], or other arterial thrombosis.

- Females of childbearing potential and males must be willing to use an effective
method of contraception (hormonal or barrier method of birth control; abstinence)
while on treatment and for a 4-week period thereafter.

- Females with childbearing potential must have a negative pregnancy test within 7 days
prior to being randomized. Patients are considered not of child bearing potential
if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal
ligation, or bilateral oophorectomy) or they are postmenopausal.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the rate of response after 3 and 6 cycles for patients with low-risk MDS

Outcome Time Frame:

24 months

Safety Issue:

No

Principal Investigator

Larry Cripe, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Hoosier Oncology Group, LLC

Authority:

United States: Institutional Review Board

Study ID:

HOG MDS04-85

NCT ID:

NCT00379912

Start Date:

September 2006

Completion Date:

December 2008

Related Keywords:

  • Myelodysplastic Syndromes
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location

Indiana University Cancer CenterIndianapolis, Indiana  46202-5265
Methodist Cancer CenterOmaha, Nebraska  68114
Arnett Cancer CareLafayette, Indiana  47904
Northern Indiana Cancer Research ConsortiumSouth Bend, Indiana  
Medical & Surgical Specialists, LLCGalesburg, Illinois  61401
Horizon Oncology CenterLafayette, Indiana  47905
Quality Cancer Center (MCGOP)Indianapolis, Indiana  46202
Medical Consultants, P.C.Muncie, Indiana  47303
Center for Hematology-Oncology of S MichiganJackson, Michigan  49201